The purpose of this clinical trial is to evaluate the weight loss effect and safety after
administration of the test drug Qsymia in obese patients.
To this end, the primary objective is to compare the weight change rate (%) between the study
groups compared to the placebo groups at week 56 after administration of the investigational
product.
The secondary objective is to compare the weight change rate (%) at each evaluation point
after administration of the investigational product, the proportions of subjects who lost
more than 5% and more than 10% of weight at each evaluation point, and changes in
weight/BMI/waist circumference/heart rate/blood pressure between the study groups compared to
the placebo groups.